that trains the patient's own immune system to target tumor cells has been developed and successfully trialed in human cancer patients.system for genetic engineering and paves the way for future advances in personalized cancer treatment.
Survival rates vary significantly between different cancer types, ranging from 98 percent for testicular cancer to just 1 percent for pancreatic cancer. On average, 67 percent of people with cancer in the U.S. will survive for at least five years after the diagnosis, and many cancers can be cured if they are detected early and treated.standard treatmentOne of the main limitations of treatments today is the difficulty of specifically targeting cancer cells while avoiding healthy ones.
A file photo of a scientist testing new therapies. Immunotherapy has emerged as a new form of cancer treatment in the last 10 years., details the first successful human trials using CRISPR technology to genetically engineer cells from the human immune system to recognize and destroy cancer cells. "We are reporting on what is very likely the most complicated treatment approach ever tried in humans: a personalized gene engineered immune cell therapy using CRISPR," Antoni Ribas of the